Short Interest in Novozymes A/S (OTCMKTS:NVZMY) Drops By 92.9%

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 8,733 shares, a decline of 92.9% from the April 15th total of 123,173 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 100,079 shares, the days-to-cover ratio is presently 0.1 days.

Novozymes A/S Trading Up 0.2%

Shares of OTCMKTS:NVZMY traded up $0.13 during mid-day trading on Tuesday, reaching $59.28. The stock had a trading volume of 20,101 shares, compared to its average volume of 94,783. The firm has a market cap of $24.57 billion, a PE ratio of 40.05, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98. The firm has a 50 day simple moving average of $58.31 and a two-hundred day simple moving average of $61.03. The company has a current ratio of 0.72, a quick ratio of 0.44 and a debt-to-equity ratio of 0.12. Novozymes A/S has a twelve month low of $49.90 and a twelve month high of $75.99.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). Novozymes A/S had a net margin of 14.22% and a return on equity of 6.57%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. On average, research analysts predict that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NVZMY. Rothschild & Co Redburn upgraded shares of Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Zacks Research lowered shares of Novozymes A/S from a “hold” rating to a “strong sell” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novozymes A/S has an average rating of “Moderate Buy”.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).